normstock

Synergy suffers from constipation of cash?

normstock Actualizado   
NASDAQ:SGYP   None
Very good news came for Synergy pharmaceuticals, the FDA approved expanded indication to treat irritable bowel for one of their products.
  However, according to some analysts seems that the company suffers from cash constipation (lol) which limits its access to loans with which it could exploit this product to the maximum.

I think it is quite interesting what can happen with this company in the next few days, I will be pending how it develops, obviously everything will depend on the level of certainty that may generate in investors, words like cash, loans and strategies will be key.
Comentarios:
Nop, not good.
Operación cerrada: precio stop alcanzado
Exención de responsabilidad

La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.